Answers are grounded in this paper and cite their sources.
Rapid antimicrobial susceptibility testing (AST) is critical in combating the rising burden of microbial infections and the global threat of antimicrobial resistance (AMR). Conventional AST methods, developed decades ago, remain the clinical gold standard and require several days to yield results, hindering timely decision-making and delaying targeted therapy. This review highlights recent phenotypic AST approaches developed since 2020 that leverage advances in microfluidics, sensing modalities, and single-cell analysis to enable rapid monitoring of microbial responses to antimicrobials. These strategies substantially reduce turnaround times, support direct testing of clinical specimens, and facilitate integration with upstream sample preparation and pathogen identification within automated, miniaturized platforms that are compatible with high-throughput workflows. Importantly, several of these technologies are being extended beyond bacterial systems to fungal pathogens, addressing a critical unmet need, as delayed antifungal susceptibility testing (AFST) continues to contribute to high morbidity and mortality. Collectively, these advances underscore the potential of sensor-integrated, rapid AST platforms to transform clinical decision-making, improve antimicrobial stewardship, and mitigate the burden of AMR.
No takes yet. Share an insight, caveat, or question.
Xin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: